Home › NCT04998552
Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma
Recruiting
Safety and Efficacy of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma: Open Label Prospective Randomized Clinical Trial
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Able to sign the informed consent and understand the consenting process * Completed neoadjuvant chemotherapy regimen * Patient is 18 years of age and older * Eastern Cooperative Oncology Group (ECOG) Status of 0-1. * Patient has a diagnosis of Stage I to Stage III pancreatic cancer cytologically or pathologically confirmed per American Joint Committee on Cancer (AJCC) staging criteria and NCCN guidelines, based on radiographic imaging or exploratory laparoscopic surgery, low degree of arterial involvement (CA, CHA, SMA) and no aorta involvement. * Patients who are deemed eligible for IMRT or SBRT and approved to receive radiation therapy by multidisciplinary tumor board * Patient shows no evidence of disease progression to distant metastasis based on NCCN. * Negative pregnancy test Exclusion Criteria: * Pregnant or lactating female patients of reproductive potential who are not willing to employ highly effective birth control from screening to 6 months after the last dose of radiation therapy. * Resectable pancreatic cancer (See addendum, NCCN Guidelines 2021, PANC-2) * Unresectable pancreatic cancer (See addendum, NCCN Guidelines 2021, PANC-6) * Patients who are unable to tolerate general anesthetic with full skeletal muscle blockade. * Patients with implanted cardiac pacemakers, defibrillators, electronic devices or implanted devices with metal parts in the thoracic cavity. * Life expectancy of \< 1 year
About the study
The hypothesize that SBRT will limit or reverse tumor growth and thereby convert the borderline resectable disease or locally advanced disease in to a resectable tumor. Furthermore, we want to assess whether SBRT leads to an improved quality of life compared to IMRT.
What is being tested
- Cyberknife (radiation)
Sponsor: Capital Health System, Inc · Participants: 10 · Started: Jun 22, 2021
Contact the study team
- Shirnett Williamson, MD · Phone: 609-303-4244
Official record on ClinicalTrials.gov — NCT04998552
Locations in the U.S.
| New Jersey | Capital Health Medical Center-Hopewell, Pennington |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.